Quantifying the Benefits of Dimethyl Fumarate Over β Interferon and Glatiramer Acetate Therapies on Work Productivity Outcomes in MS Patients

Overview of attention for article published in Neurology and Therapy, January 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (77th percentile)
Above-average Attention Score compared to outputs of the same age and source (57th percentile)

Mentioned by

policy: 2 policy sources

twitter: 1 X user

Citations

dimensions_citation: 14 Dimensions

Readers on

mendeley: 33 Mendeley

Summary Policy documents X Dimensions citations

So far, Altmetric has seen 2 policy documents that reference this research output.

Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis : Committee papers

Cited by National Institute for Health and Care Excellence on 15 Jan 2020

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Sykdomsbegrensende legemidler for behandling av attakkpreget multippel sklerose, inkludert rituximab. En metodevurdering

Cited by Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) on 27 Aug 2019

SBU is an independent national authority, tasked by the government with assessing health care and social service interventions from a broad perspective, covering medical, economic, ethical and social aspects.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.